Letter: Electromechanical Improvement Without Clinical Endpoints: How Far Can We Go?

Erzurum M Felekoğlu MA Algül NIE , et al. Effect of SGLT2 inhibitors on atrial electromechanical delay in patients with type 2 diabetes. Angiology. Published online March 2026. doi:10.1177/00033197261427837

Zhang HD Ding L Mi LJ , et al. Sodium-glucose cotransporter-2 inhibitors for the prevention of atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol. 2024;31:770-779.

Wang J Qi S Chen S Yu H. Effect of SGLT2 inhibitors on atrial fibrillation in patients with type 2 diabetes and dilated cardiomyopathy: a cohort study. Cardiovasc Ther. 2026;2026:5113761.

De Vos CB Weijs B Crijns HJ , et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart. 2009;95:835-840.

Pytkowski M Jankowska A Maciag A , et al. Paroxysmal atrial fibrillation is associated with increased intra-atrial conduction delay. Europace. 2008;10:1415-1420.

Li WJ Chen XQ Xu LL Li YQ Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19:130.

Shao Q Meng L Lee S , et al. Empagliflozin alleviates atrial remodeling and improves mitochondrial function in diabetic models. Cardiovasc Diabetol. 2019;18:165.